Researchers at the Spanish National Cancer Research Center (CNIO) propose a new treatment for brain metastases that respond ...

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class ...

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumorsPreclinical ...

A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for ...

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

An oncologist tells PEOPLE about the innovative cancer treatment that extended the former president’s life as he celebrates ...

In a follow-up study, researchers compared cancer immunotherapy in mice, using either single or double immune responses. And ...

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

Thanks to early detection through widespread screening and dramatic breakthroughs in immunotherapy and other cancer ...

North America Cancer Immunotherapy Market is expanding rapidly due to expanding approval of immunotherapeutic drugs for the treatment of increasing incidences of cancer and increasing investments in ...